Abstract
Gilteritinib induces 2 distinct marrow responses in FLT3-mutated AML: responses with and without differentiation.
Ongoing clonal hematopoiesis is ubiquitous during gilteritinib therapy and may promote genetic evolution and drug resistance.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aniline Compounds / pharmacology
-
Aniline Compounds / therapeutic use*
-
Cell Differentiation
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / genetics*
-
Pyrazines / pharmacology
-
Pyrazines / therapeutic use*
-
Recurrence
-
fms-Like Tyrosine Kinase 3 / metabolism*
Substances
-
Aniline Compounds
-
Pyrazines
-
gilteritinib
-
FLT3 protein, human
-
fms-Like Tyrosine Kinase 3